An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease

« Previous Next »European Neuropsychopharmacology
Volume 20, Issue 8 , Pages 582-593, August 2010

An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D₂/D₃ receptor partial agonist and 5-HT_1A receptor agonist with efficacy in experimental models of Parkinson's disease

C.A. Jones
- Abbott Pharmaceuticals B.V., Weesp, The Netherlands (formerly Solvay Pharmaceuticals B.V.)
- These authors contributed equally.
- Present address: School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK.
L.C. Johnston
- Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King's College London, London SE1 1UL, UK
- These authors contributed equally.
- Present address: Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
M.J. Jackson
- Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King's College London, London SE1 1UL, UK
L.A. Smith
- Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King's College London, London SE1 1UL, UK
G. van Scharrenburg
- Abbott Pharmaceuticals B.V., Weesp, The Netherlands (formerly Solvay Pharmaceuticals B.V.)
S. Rose
- Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King's College London, London SE1 1UL, UK
P.G. Jenner
- Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King's College London, London SE1 1UL, UK
A.C. McCreary
- Abbott Pharmaceuticals B.V., Weesp, The Netherlands (formerly Solvay Pharmaceuticals B.V.)
- Corresponding author. Tel.: +31 294 479 514; fax: +31 294 410 069.